Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Extension Study of Cendakimab in Eosinophilic Esophagitis
2023-506278-10-00Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 14
01
Overview
Phase 3, open-label, single-arm trial of cendakimab in eosinophilic esophagitis (EoE), sponsored by Celgene Corporation. Primary endpoint: Safety and tolerability of long-term treatment with CC-93538. Started Apr 2024; status: completed.
02
Drugs
cendakimab
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on 2023-506278-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506278-10-00.